https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/318 2026-07-03T23:21:56Z https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/210818 Title: Emerging electronic deodorization technologies for human odor management Authors: Lee, Solpa; Diwe, Pratiksha; Lim, Tae Ho; Jang, Yongwoo Abstract: [No abstract available] 2026-09-01T00:00:00Z https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/214436 Title: Association of GLP-1 Receptor Agonists With Hepatic Decompensation in the All of Us Research Program Authors: Hwang, Inyoung; Kim, Yun; Lee, Sang Won Abstract: Aims To evaluate the association between glucagon-like peptide-1 receptor agonist (GLP-1RA) initiation and the risk of hepatic decompensation compared with dipeptidyl peptidase 4 inhibitors (DPP4is) in a racially and ethnically diverse cohort of adults with Type 2 diabetes.Materials and Methods This retrospective active-comparator new-user cohort study utilised data from the National Institutes of Health's All of Us Research Program. Adult participants with Type 2 diabetes initiating GLP-1RAs or DPP4is without prior hepatic decompensation or competing causes of chronic liver disease were identified. Stratified propensity score matching (1:1) was employed to balance baseline covariates. The primary outcome was a composite of hepatic decompensation events (oesophageal varices with bleeding, ascites, hepatic encephalopathy, hepatic failure, or liver transplantation). Hazard ratios (HRs) were estimated using Cox proportional hazards regression.Results The matched cohort included 7854 participants (mean age 57.3 years; 58.8% female; 24.8% Black or African American). GLP-1RA use was associated with a significantly reduced risk of hepatic decompensation compared with DPP4i use (HR 0.67; 95% CI 0.47-0.95; p = 0.026), corresponding to an absolute rate difference of -1.66 events per 1000 person-years. Estimates were directionally similar in prespecified sensitivity analyses.Conclusions In this diverse nationwide cohort, initiation of GLP-1RAs was associated with a significantly reduced risk of hepatic decompensation compared with DPP4is. These findings extend prior evidence by demonstrating this association in a cohort enriched for populations historically underrepresented in biomedical research. 2026-06-01T00:00:00Z https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/217750 Title: 통증 및 부종 관리를 위한 공랭식 중주파 의료기기의 임상적 유효성과 안전성: 후향적 다기관 연구 Authors: 안창훈; 김수용; 김아란; 강륜; 임소정; 강주섭 Abstract: 본 연구는 공랭식 중주파 의료기기 쿨리온(Coollion™)의 통증 및 부종 완화에 대한 임상적 유효성을 평가하였다. 쿨리온은 접촉식 전도성 열 자극(냉각 및 온열)과 중주파 전기 자극이 조합된 비침습적 기기로, 전용 전도성 겔(coolion gel)과 함께 사용된다. 3개 기관의 급·만성 통증 및 부종 환자 150명을 대상으로 후향적 분석을 한 결과, 통증이 있는 환자 150명에서 치료 전 통증 VAS 점수의 중앙값은 6.06에서 치료 후 2.79로 유의하게 감소하였으며(p < 0.001), 부종 증상이 있는 환자 98명에서도 VAS 점수의 중앙값이 6.92에서 2.50으로 유의하게 감소하였다(p < 0.001). 다중 선형회귀분석 결과, 초기 증상 강도가 높을수록(p < 0.001) 치료 반응이 크게 나타났으며, 두경부 부위에 적용한 경우 더 큰 감소가 관찰되었다(p < 0.001). 이러한 효과는 근막통증, 하복부통증, 임플란트 및 발치 후 통증과 부종 등 다양한 임상 증례에서 일관되게 관찰되었다. 분석된 150건의 사례 모두에서 부작용이나 이상반응은 보고되지 않았다. 결론적으로 쿨리온 치료는 통증 및 부종 관리에서 약물 요법 등의 한계를 보완할 수 있는 안전하고 효과적인 비침습적 치료 대안이 될 것으로 사료된다.; This study evaluated the clinical efficacy of 'Coollion™', an air-cooled mid-frequency medical device, for managing pain and edema. Coollion is a non-invasive multimodal device that integrates contact-based conductive thermal stimulation (both cooling and heating) with mid-frequency electrical stimulation, utilized in combination with a specialized conductive gel (Coolion gel). A retrospective analysis was conducted on 150 patients with acute or chronic pain and edema at three institutions. Among patients with pain(n = 150), the median VAS pain score significantly decreased from 6.06 before treatment to 2.79 after treatment(p < 0.001). In pateints with edema(n = 98), the median VAS edema score also significantly decreased from 6.92 to 2.50(p < 0.001). Multiple regression analysis revealed that greater treatment responses were associated with higher baseline symptom severity(p < 0.001), and larger reductions were observed when the device was applied to the craniofacial region(p < 0.001). Consistent efficacy was observed across various clinical conditions, including myofascial pain, lower abdominal pain, and post-operative pain and edema following dental implants or extractions. Furthermore, no adverse events or side effects were reported in any of the 150 cases. In conclusion, Coollion therapy presents a promising, safe, and effective non-invasive alternative for the management of pain and edema that can overcome the limitations of conventional pharmacological interventions. 2026-05-01T00:00:00Z https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/211356 Title: Model-informed prediction of human pharmacokinetics and first-in-human dose selection of J2H-1702, a novel 11(3-hydroxysteroid dehydrogenase type 1 inhibitor for metabolic-associated steatohepatitis Authors: Kim, Inkyu; Hwang, Inyoung; Lee, Sang Won; Kim, Yun Abstract: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease with limited therapeutic options. J2H-1702 is a novel and selective inhibitor of 11(3-hydroxysteroid dehydrogenase type 1 (11(3-HSD1) that has demonstrated pharmacological activity in preclinical models. This study aimed to predict the human pharmacokinetics (PK) of J2H-1702 and support rational first-in-human (FIH) dose selection using a modelinformed approach. Plasma PK data following intravenous and oral administration were obtained from Sprague-Dawley rats and Beagle dogs and analyzed using non-compartmental analysis and nonlinear mixed-effects modeling. Less-than-dose-proportional increases in systemic exposure were observed following oral administration in both species. This nonlinear exposure behavior was explicitly characterized using a nonlinear bioavailability model and incorporated into an interspecies pharmacokinetic framework. Interspecies extrapolation was performed using multiple allometric scaling approaches, including body weight-based, maximum lifespan potential-adjusted, brain weight-adjusted, and multiple-exponent models. Among these, the brain weight-adjusted model showed the best predictive performance. The final model was used to simulate human PK profiles across oral dose levels. Simulations predicted that doses >= 3 mg would maintain plasma concentrations above the in vitro half-maximal inhibitory concentration for 11(3-HSD1 inhibition for approximately 48 hours. In parallel, no-observed-adverse-effect level-based calculations supported a substantially higher maximum recommended starting dose, indicating a wide safety margin. Integration of exposure-based pharmacodynamic criteria with toxicology-based constraints supported selection of 3 mg as a conservative and pharmacologically relevant FIH starting dose. These findings demonstrate the utility of model-informed PK analysis for translating preclinical data into rational FIH dose selection in early clinical development. 2026-04-01T00:00:00Z